Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7250096 | 0.98 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL16086477 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL11566214 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL1636834 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| Bromide SCHEMBL15825597 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| Hydrochloric Acid SCHEMBL7249126 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL7453226 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| Bromide SCHEMBL1636830 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL999630 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL18696308 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1TSHRL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-115403558-A | Aromatic heterocyclic compound with antitumor activity and preparation method and application thereof | 河南真实生物科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2022148196-A1 | MULTIKINASE INHIBITOR AND USE THEREOF | 苏州安睿药业有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3526206-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| CN-1267431-C | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| EP-0996617-B1 | 2,4-Dithi(oxo)-pyridin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists | ASTRAZENECA AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| US-6107297-A | 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-08-22 | — | — | US | disclosed |
| EP-0996617-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999002501-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| US-5049558-A | Quaternized nitrogen-heterocycle substituted | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-09-17 | — | — | US | disclosed |
| EP-0164944-B1 | CEPHALOSPORIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-11 | — | — | EP | disclosed |
| EP-0164944-A1 | Cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-18 | — | — | EP | disclosed |
| US-4254260-A | 3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | SMN1; SMN2 320/4885ALDH1A1 222/4885TSHR 3838/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | SMN1; SMN2 320/4885ALDH1A1 222/4885TSHR 3838/4885 |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | SMN1; SMN2 1955/4885ALDH1A1 2921/4885TSHR 3775/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | SMN1; SMN2 1360/4885ALDH1A1 494/4885TSHR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.